Clene Boosts Production Capacity of CNM-Au8

Clene Boosts Production Capacity of CNM-Au8

303437

Clene Boosts Production Capacity of CNM-Au8

Clene, and its wholly owned subsidiary Clene Nanomedicine, have signed two lease agreements that will more than quadruple the manufacturing capacity of CNM-Au8, their investigational therapy for people with amyotrophic lateral sclerosis (ALS). The first lease is for a 10-year agreement for a 74,210-square-foot building in Elkton, Maryland. The second is a seven-year lease pertaining to the expansion of its existing manufacturing site in North East, Maryland, to a total of 32,229 square feet. Both…

You must be logged in to read/download the full post.